Safe and effective booster immunization using DTaP in teenagers.
The incidence of reported cases with pertussis has increased in young adults in Japan and the lack of additional booster immunizations containing pertussis components is suspected to be one of the causal reasons. Instead of DT immunization at 11-12 years of age, safety and immunogenicity were investigated using 0.2 ml and 0.5 ml of DTaP. 176 subjects in DTaP 0.5ml, 178 in DTaP 0.2 ml, and 197 in DT 0.1 ml groups were enrolled in clinical trial. The relative risk of local reactions in the DTaP 0.2 ml group compared to the DT 0.1 ml group was 1.13 (95% CI: 0.97-1.30), and that of the DTaP 0.5 ml to the DT 0.1 ml group was 1.34 (95% CI: 1.18-1.53). The relative risks of local pain and heat were 1.62 (95% CI: 1.33-1.98) and 1.59 (95% CI: 1.19-2.13), respectively, in the DTaP 0.5 ml group compared to the DT 0.1 ml group. Sero-positive rates against PT and FHA were 54% and 82% before immunization and increased to >95% for both after vaccination with no significant difference in GMT. Instead of the scheduled DT program, 0.2 ml of DTaP was acceptable and demonstrated efficient immunogenicity.
Okada
Kenji
K
National Fukuoka Hospital, Department of Pediatrics, Japan.
Komiya
Takako
T
Yamamoto
Akihiko
A
Takahashi
Motohide
M
Kamachi
Kazunari
K
Nakano
Takashi
T
Nagai
Takao
T
Okabe
Nobuhiko
N
Kamiya
Hitoshi
H
Nakayama
Tetsuo
T
D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood; D002648:Child; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D015994:Incidence; D007564:Japan; D008297:Male; D014917:Whooping Cough / Q000276:immunology / Q000517:prevention & control*
D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine